Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study.

@article{Ong2015AIW,
  title={Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study.},
  author={Kevin Ong and Victor Villemagne and Alex Bahar-Fuchs and Fiona Lamb and Narelle Langdon and Ana M. Catafau and Andrew W. Stephens and John P. Seibyl and Ludger M. Dinkelborg and Cornelia Reininger and Barbara Putz and Beate Rohde and Colin L. Masters and Christopher C. Rowe},
  journal={Journal of neurology, neurosurgery, and psychiatry},
  year={2015},
  volume={86 4},
  pages={431-6}
}
BACKGROUND We assessed the clinical utility of β-amyloid (Aβ) imaging with (18)F-florbetaben (FBB) in mild cognitive impairment (MCI) by evaluating its prognostic accuracy for progression to Alzheimer's disease (AD), comparing semiquantitative with visual scan assessment, and exploring the relationships among Aβ, hippocampal volume (HV) and memory over time. METHODS 45 MCI underwent FBB positron emission tomography, MRI and neuropsychological assessment at baseline and 2 years and clinical… CONTINUE READING